XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment (Details) - CODM [Member] - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment [Line Items]        
Clinical Study Expense $ 1,083,100 $ 2,345,300 $ 9,823,300 $ 7,105,400
Other Research Expense 852,800 5,956,400 3,386,000 19,262,700
Manufacturing and Drug Storage Expense 752,000 301,400 989,200 1,275,400
Pre-clinical Expense 33,700
Compensation Expense 990,400 805,300 2,986,500 2,478,300
Stock-based Compensation Expense 358,000 1,740,700 1,621,700 5,020,000
Total Research and Development Expense $ 4,036,300 $ 11,149,100 $ 18,806,700 $ 35,175,500